BELLICUM PHARMACEUTICALS INC (BLCM) Stock Overview
USA - NASDAQ:BLCM - US0794814048 - Common Stock
BLCM Key Statistics, Chart & Performance
The current stock price of BLCM is 0.622 USD. In the past month the price increased by 64.03%. In the past year, price decreased by -47.29%.
BLCM Latest News, Press Relases and Analysis
BLCM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About BLCM
Company Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2014-12-18. The firm is focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Its Chemical Induction of Dimerization (CID), technology platform is designed to enable control of components of the immune system in real time. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. The company has developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cell.
Company Info
BELLICUM PHARMACEUTICALS INC
3730 Kirby Drive, Suite 1200
Houston TEXAS 77098 US
CEO: Richard A. Fair
Employees: 13
Phone: 18323841100.0
BELLICUM PHARMACEUTICALS INC / BLCM FAQ
Can you describe the business of BELLICUM PHARMACEUTICALS INC?
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2014-12-18. The firm is focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Its Chemical Induction of Dimerization (CID), technology platform is designed to enable control of components of the immune system in real time. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. The company has developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cell.
What is the stock price of BELLICUM PHARMACEUTICALS INC today?
The current stock price of BLCM is 0.622 USD. The price decreased by -9.72% in the last trading session.
Does BLCM stock pay dividends?
BLCM does not pay a dividend.
How is the ChartMill rating for BELLICUM PHARMACEUTICALS INC?
BLCM has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists BLCM stock?
BLCM stock is listed on the Nasdaq exchange.
Would investing in BELLICUM PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BLCM.
BLCM Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLCM. When comparing the yearly performance of all stocks, BLCM is a bad performer in the overall market: 90.07% of all stocks are doing better.
BLCM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLCM. BLCM has a bad profitability rating. Also its financial health evaluation is rather negative.
BLCM Financial Highlights
Over the last trailing twelve months BLCM reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS decreased by -183.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
BLCM Forecast & Estimates
6 analysts have analysed BLCM and the average price target is 5.1 USD. This implies a price increase of 719.94% is expected in the next year compared to the current price of 0.622.
For the next year, analysts expect an EPS growth of 38.37% and a revenue growth -100% for BLCM